Commonly used mouse models for testing α-syn and tau therapies fall into two main categories: (1) genetically modified rodent models that overexpress mutated human α-syn or tau, such as A53T (M83), A30P under different promoters (PLP/Thy-1) [133, 134, 143, 144], and tau P301L/S, which predominantly models for FTLD rather than AD [165, 235]; and (2) rodent models inoculated with patient-derived or in vitro-produced PFFs to induce endogenous α-syn and tau aggregation, mimicking the protein aggregation and propagation processes observed in different neurodegenerative diseases [126]. This evidence concerns the gene MAPT and Alzheimer disease.